Connect your AI

Veradermics MANE Value of common stock issued to settle convertible senior notes

Value of common stock issued to settle convertible senior notes at other companies

Oscar HealthOSCR

$70.83M—

CytokineticsCYTK

$26.98M—

AST SpaceMobileASTS

$0-100%

ZscalerZS

$1K—

SemtechSMTC

——

NexPoint Real Estate FinanceNREF

——

Other financials

Income statement

Operating income-$29.9M-131%

Net income-$27.2M-120%

EPS (diluted)-$1.32+93.3%

Balance sheet

Cash & equivalents$168.4M+419%

Total debt$4.0K—

Total equity$390.6M+744%

Total assets$397.4M—

Cash flow

Operating cash flow-$21.2M-59.0%

CapEx--100%

Free cash flow-$21.2M-58.7%

Valuation

Market cap$3.92B—

Returns & leverage

Return on equity-28.7%—

Current ratio59.1×—

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:DebtConversionConvertedInstrumentAmount1.

The official record: Veradermics ’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veradermics 's value of common stock issued to settle convertible senior notes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Veradermics 's value of common stock issued to settle convertible senior notes?: Veradermics (MANE) reported value of common stock issued to settle convertible senior notes of $0 in Q4 2025.
How has Veradermics 's value of common stock issued to settle convertible senior notes changed year-over-year?: Veradermics 's value of common stock issued to settle convertible senior notes decreased by 100.0% year-over-year, from $2.61M to $0.